Biosimilars saved 1.000 million euros to the National Health System in 2022, 6,7% more than the previous year (937 million) and 14,6% more than in 2020 (872 million). The trend indicates that savings are increasing and will continue to do so for years. A report published in The Economist, in which they have had the opinion of BioSim.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
